Cogent Biosciences, Inc.
Financials
Valuation Metrics
Cogent Biosciences, Inc.'s Market Cap is $5.30B. At end of 2025 it was $2.40B. Ranked #1294 of 3,114 in US market (top 42%), #437 of 1,469 on NASDAQ (top 30%), #73 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 28%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.30B | US#1,294/3,114 Sec#73/265 |
| Revenue | $0.00 | US#2,862/3,114 Sec#194/265 |
| Net Income | $-377M | US—/3,114 Sec—/265 |
| Total Assets | $835M | US#2,546/3,114 Sec#115/265 |
| Net Assets | $532M | US#2,185/3,114 Sec#102/265 |
| Employees | 258 | US#2,440/3,114 Sec#119/265 |
| Value | ||
| P/B | 9.95x | US#2,623/3,114 Sec#196/265 |
| FCF Yield | -5.84% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -70.85% | US#2,748/3,114 Sec#189/265 |
| ROA | -45.20% | US#2,967/3,114 Sec#202/265 |
| Financial Health | ||
| Debt Ratio | 56.76% | US#649/3,114 Sec#141/265 |
| Total Debt | $244M | US#2,184/3,114 Sec#91/265 |
| FCF | $-309M | US#2,859/3,114 Sec#236/265 |
| Cash | $181M | US#1,811/3,114 Sec#120/265 |
| Current Ratio | 13.57x | US#182/3,114 Sec#55/265 |
| Performance | ||
| 1Y Return | 91.24% | US#117/3,114 Sec#28/265 |
| 1M Return | -3.19% | US#1,864/3,114 Sec#100/265 |
| From 52W High | -29.11% | US#1,876/3,114 Sec#110/265 |
| 1Y MDD | -34.43% | US#1,607/3,114 Sec#88/265 |
| Trading | ||
| Volume | 2,101,393 shares | US#1,413/3,114 Sec#126/265 |
| Trading Value | $66M | US#1,554/3,114 Sec#100/265 |
| Per Share | ||
| EPS | $-2.21 | US—/3,114 Sec—/265 |
| BPS | $3.12 | US#2,472/3,114 Sec#160/265 |
Company Info
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.